Shuichiro Shiina
Overview
Explore the profile of Shuichiro Shiina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
5820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki A, Sano K, Saito Y, Wijeratne P, Yamamoto K, Fujita S, et al.
Cureus
. 2025 Mar;
17(2):e78744.
PMID: 40065901
Background and aim The natural progression of liver fibrosis and its association with biomarker changes have not been fully established in the literature. This study aimed to investigate liver fibrosis...
2.
Shiina S, Maikhuu J, Deng Q, Batsaikhan T, Canseco L, Tobari M, et al.
Clin Mol Hepatol
. 2025 Mar;
PMID: 40037692
Liver disease has emerged as a critical and escalating public health concern worldwide, with the Asia-Pacific region at the forefront of this challenge due to its vast population and diverse...
3.
Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A, et al.
Hepatol Int
. 2025 Feb;
19(1):1-69.
PMID: 39961976
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the...
4.
Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, et al.
Hepatol Int
. 2024 Nov;
18(6):1661-1683.
PMID: 39570557
In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs...
5.
Sato M, Tateishi R, Moriyama M, Fukumoto T, Yamada T, Nakagomi R, et al.
Gastro Hep Adv
. 2024 Aug;
1(1):29-37.
PMID: 39129938
Background And Aims: Radiofrequency ablation (RFA) is a widely accepted, minimally invasive treatment for hepatocellular carcinoma (HCC). This study aimed to develop a machine learning (ML) model to predict the...
6.
Sekino Y, Tateishi R, Fukumitsu N, Okumura T, Maruo K, Iizumi T, et al.
Liver Cancer
. 2023 Oct;
12(4):297-308.
PMID: 37817755
Introduction: Proton beam therapy (PBT) is known to be an effective locoregional treatment for hepatocellular carcinoma (HCC). However, few comparative studies in treatment-naïve cases have been reported. The aim of...
7.
Sato M, Moriyama M, Fukumoto T, Yamada T, Wake T, Nakagomi R, et al.
Hepatol Int
. 2023 Sep;
18(1):131-137.
PMID: 37689614
Introduction: Radiofrequency ablation (RFA) is a widely accepted, minimally invasive treatment modality for patients with hepatocellular carcinoma (HCC). Accurate prognosis prediction is important to identify patients at high risk for...
8.
Iijima H, Kudo M, Kubo S, Kurosaki M, Sakamoto M, Shiina S, et al.
Hepatol Res
. 2023 Aug;
53(10):895-959.
PMID: 37574758
For the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20 889 newly registered patients and 42 274 previously registered follow-up patients were compiled from 516...
9.
Shiina S, Maruyama H, Tobari M, Yamashita T
Hepatol Int
. 2023 May;
17(4):827-829.
PMID: 37188999
No abstract available.
10.
Saeki M, Okubo H, Takasaki Y, Nakadera E, Fukuo Y, Fukada H, et al.
J Clin Med
. 2023 Apr;
12(7).
PMID: 37048744
This study investigated the impact of partial splenic embolization (PSE) on portal hypertensive gastropathy (PHG). We retrospectively analyzed endoscopic findings and the portal venous system of 31 cirrhotic patients with...